Literature DB >> 28429237

Atypical and anaplastic meningioma: outcomes in a population based study.

T Garzon-Muvdi1, W Yang1, M Lim1, H Brem1, J Huang2.   

Abstract

Atypical and anaplastic meningiomas (AAM) are aggressive tumors. This study is aimed at examining associations between patient and tumor-related factors and tumor-related death in patients with AAM. We conducted a population-based cohort study utilizing prospectively collected data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with diagnosis of AAM from 1973 to 2012 in the SEER database were included. Patients lacking clinical information were excluded. Multivariate analysis between patient and lesion characteristics, and AAM-related death was performed to adjust for confounding factors. We identified and included 522 patients in our study. Mean age at diagnosis was 60.8 ± 15.7 years. The majority of patients were White(73%), 15.5% Black, and 9.8% Asian. Average tumor size was 48.2 ± 20.3 mm. The tumor was locally confined in 57.1%, whereas it had intracranial extension in 29.3%, and extracranial extension in 8.8% of patients. The vast majority (94.8%) of tumors were supratentorial. Gross total resection (GTR) was documented in 65.5% of patients. Age at diagnosis (p = 0.001), tumor size (p = 0.003), surgery result (GTR vs. subtotal resection, p = 0.027), and radiation therapy (p = 0.2) were found to be significantly different between the comparison groups. In a multivariate proportional competing risk regression analysis age (HR 1.03, CI [1.01,1.04], p < 0.001), infratentorial location (HR 2.81, CI [1.20, 6.56], p = 0.017), tumor size (HR 1.01, CI [1.00,1.02], p = 0.032),and radiation treatment (HR 1.52, CI [1.11, 2.09], p = 0.01) were significantly associated with tumor-related death. The association of age at diagnosis, tumor size, location, and radiotherapy with overall survival in patients with AAM is demonstrated. The results provide a context for individualized treatment plans in patients with AAM. Additional studies focusing on issues such as the use of radiation and chemotherapy will clarify the best modality to achieve disease control.

Entities:  

Keywords:  Atypical meningioma; Extent of resection; Radiation

Mesh:

Year:  2017        PMID: 28429237     DOI: 10.1007/s11060-017-2436-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Regression modeling of competing risk using R: an in depth guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

2.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

3.  Model selection in competing risks regression.

Authors:  Deborah Kuk; Ravi Varadhan
Journal:  Stat Med       Date:  2013-02-24       Impact factor: 2.373

4.  Osteopontin predicts the behaviour of atypical meningioma.

Authors:  Chih-Kung Lin; Wen-Chiuan Tsai; Yu-Chun Lin; Dueng-Yuan Hueng
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

Review 5.  Management of Atypical and Anaplastic Meningiomas.

Authors:  Simon Buttrick; Ashish H Shah; Ricardo J Komotar; Michael E Ivan
Journal:  Neurosurg Clin N Am       Date:  2016-02-20       Impact factor: 2.509

6.  World Health Organization Grade II Meningioma: A 10-Year Retrospective Study for Recurrence and Prognostic Factor Assessment.

Authors:  Charles Champeaux; Laurence Dunn
Journal:  World Neurosurg       Date:  2016-02-02       Impact factor: 2.104

Review 7.  The role of adjuvant radiotherapy after gross total resection of atypical meningiomas.

Authors:  Shaakir Hasan; Michael Young; Trevine Albert; Ashish H Shah; Christian Okoye; Amade Bregy; Simon S Lo; Fazilat Ishkanian; Ricardo J Komotar
Journal:  World Neurosurg       Date:  2014-12-19       Impact factor: 2.104

8.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 9.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

Authors:  Winward Choy; Won Kim; Daniel Nagasawa; Stephanie Stramotas; Andrew Yew; Quinton Gopen; Andrew T Parsa; Isaac Yang
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

10.  Methylation markers of malignant potential in meningiomas.

Authors:  Jaime Vengoechea; Andrew E Sloan; Yanwen Chen; Xiaowei Guan; Quinn T Ostrom; Amber Kerstetter; Devan Capella; Mark L Cohen; Yingli Wolinsky; Karen Devine; Warren Selman; Gene H Barnett; Ronald E Warnick; Christopher McPherson; E Antonio Chiocca; J Bradley Elder; Jill S Barnholtz-Sloan
Journal:  J Neurosurg       Date:  2013-08-09       Impact factor: 5.115

View more
  11 in total

1.  De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.

Authors:  Brett J Theeler
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

2.  Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.

Authors:  Dorota Lubgan; Sandra Rutzner; Ulrike Lambrecht; Karl Rössler; Michael Buchfelder; Ilker Eyüpoglu; Rainer Fietkau; Sabine Semrau
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

3.  Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age.

Authors:  Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-02       Impact factor: 4.553

Review 4.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

5.  A rare subtype of meningioma: Case series of anaplastic meningioma and review of the literature.

Authors:  Hongyi Cao; Biying Jiang; Yang Zhao; Chuifeng Fan
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

6.  Integrated Transcriptomic Analysis Reveals the Molecular Mechanism of Meningiomas by Weighted Gene Coexpression Network Analysis.

Authors:  Biao Yang; Shuxun Wei; Yan-Bin Ma; Sheng-Hua Chu
Journal:  Biomed Res Int       Date:  2020-06-10       Impact factor: 3.411

7.  Individual-patient prediction of meningioma malignancy and survival using the Surveillance, Epidemiology, and End Results database.

Authors:  Jeremy T Moreau; Todd C Hankinson; Sylvain Baillet; Roy W R Dudley
Journal:  NPJ Digit Med       Date:  2020-01-30

8.  Tumor recurrence in parasagittal and falcine atypical meningiomas invading the superior sagittal sinus.

Authors:  Andrei Ionuţ Cucu; Mihaela Dana Turliuc; Claudia Florida Costea; Cristina Gena Dascălu; Gabriela Florenţa Dumitrescu; Anca Sava; Şerban Turliuc; Dragoş Viorel Scripcariu; Ion Poeată
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

9.  Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.

Authors:  Xin Tang; Fujun Liu; Zhiyong Liu; Yi Cao; Zongliang Zhang; Yuelong Wang; Jianhan Huang; Shuangming Fan; Shasha Zhao; Yaxin Chen; Gaowei Li; Shan Wang; Meijun Zheng; Yating Hu; Hongjian Li; Caiying Jiang; Meijia Yang; Hui Yang; JianGuo Xu; Gang Guo; Aiping Tong; Liangxue Zhou
Journal:  Clin Transl Immunology       Date:  2020-06-12

10.  Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas.

Authors:  Depei Li; Pingping Jiang; Shijie Xu; Cong Li; Shaoyan Xi; Ji Zhang; Yinsheng Chen; Xiaobing Jiang; Xiangheng Zhang; Ke Sai; Jian Wang; Yonggao Mou; Chao Ke; Zhongping Chen
Journal:  J Neurooncol       Date:  2019-09-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.